查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095174

內視鏡逆行性胰造影（ERCP）市場－2026-2032年全球市場預測

Endoscopic Retrograde Cholangiopancreatography Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，內視鏡逆行性造影(ERCP) 市場將成長至 38.7 億美元，複合年成長率為 8.28%。

主要市場統計數據
基準年 2025 22.1億美元
預計年份：2026年 23.9億美元
預測年份 2032 38.7億美元
複合年成長率 (%) 8.28%

內視鏡逆行性胰造影（ERCP）執行摘要

內視鏡逆行性造影（ERCP）是一種專門的微創手術，用於診斷和治療膽管和胰臟系統的疾病，包括膽道結石、膽管狹窄、胰管漏、膽管炎和惡性膽道阻塞。 ERCP結合了內視鏡和透視影像技術，最初主要用於診斷，但現在已發展成為消化內科、肝膽胰內科和介入內視鏡治療的基礎。其臨床價值在取石、括約肌切開術、膽道支架置入、組織取材、引流和術後併發症處理方面尤其重要。

ERCP領域的變革性變化

隨著治療效果的提升、技術的進步以及對安全性的日益重視，ERCP正經歷著一場變革。隨著非侵入性影像技術，特別是磁振造影造影（MRCP）和內視鏡超音波的廣泛應用，診斷性ERCP在許多先進的醫療機構中逐漸減少。因此，ERCP的應用範圍日益局限於預期需要直接干預的病例，例如膽管結石取出、支架置入、膽管阻塞減壓以及良惡性狹窄的治療。

人工智慧（AI）對內視鏡逆行性胰膽管攝影術（ERCP）的累積影響

人工智慧 (AI) 正透過影像解讀、工作流程最佳化、臨床決策支援、培訓和品質改進等方式，開始影響內視鏡逆行性胰膽管造影 (ERCP) 的生態系統。雖然 AI 在電腦輔助病變檢測 (CAD) 等內視鏡應用領域已較為成熟，但隨著高品質手術影片、透視影像、電子健康記錄和內視鏡報告系統變得更加結構化和易於分析，其在 ERCP 中的重要性也日益凸顯。

關於ERCP實施的關鍵區域見解

在亞太地區，隨著先進內視鏡服務的普及、膽結石和肝膽疾病患者群體大規模、三級醫療網路不斷擴展，以及主要城市醫院內超音波超音波和膽道鏡檢查的日益普及，ERCP 的應用正在不斷成長。在醫療基礎設施成熟的國家，重點在於建造高容量內視鏡中心、完善感染控制流程、普及先進的透視技術以及開展治療性內視鏡培訓；而在醫療體系尚不成熟的國家，則更注重系統建設、確保專科醫生的配備以及可靠地獲取必要的 ERCP 設備。

醫療保健和經濟區主要群體分析

在東協地區，三級醫療基礎設施的擴建、胃腸和肝膽疾病診斷數量的增加以及都市區對先進內視鏡中心的投資增加，正在推動ERCP的發展。該地區的多樣性導致了ERCP普及率的差異：醫療體系較為發達的國家更注重複雜的治療性ERCP，而新興市場則優先考慮訓練有素的內視鏡醫師的廣泛普及、透視支持、器械消毒能力以及必要配件的供應。

主要國家內視鏡逆行性造影（ERCP）分析

在美國，ERCP（內視鏡逆行胰膽管攝影）已建立起高度發展的體系，這得益於先進的內視鏡專科訓練、完善的醫院胰膽疾病診療項目，以及對十二指腸內視鏡安全性、ERCP術後胰臟炎預防和手術品質指標的高度重視。加拿大同樣強調實證醫學的應用、集中化的先進內視鏡技術，以及如何確保地域分散的人群都能公平地獲得醫療服務。在墨西哥，儘管都市區專科醫療中心和私營部門的投資正在提升ERCP的普及率，但公共醫療機構的准入、保險報銷的差異以及訓練有素的人員分佈等問題仍然影響著該手術的廣泛應用。

為ERCP產業領導者提供的實用建議

產業領導者應優先發展能夠提升ERCP安全性、治療準確性和可靠性的技術和服務。醫療設備開發商可以專注於開發能夠減少插管創傷、改善結石清除、提高支架置入精度以及適應複雜解剖結構的配件。對一次性產品和易於再處理的組件日益成長的需求，有助於解決因十二指腸內視鏡設計和清潔的複雜性而長期存在的感染控制問題。

理解ERCP的調查方法

本執行摘要採用系統化的二手研究途徑編寫，重點關注經臨床檢驗和與行業相關的資訊。該調查方法整合了同行評審的胃腸病學文獻、國際臨床實踐指南、監管安全資訊、公共衛生機構資料、醫院品管框架以及內視鏡再處理、手術安全和不利事件預防的既定標準。

結論：ERCP作為一種精準治療平台

內視鏡逆行性造影（ERCP）仍是胰膽疾病治療的關鍵手段。當患者需要取出膽管結石、進行膽道引流、置入支架、進行括約肌切開術、取組織或治療複雜狹窄時，ERCP 的重要性尤其突出。儘管非侵入性影像技術的進步降低了單純出於診斷目的而進行 ERCP 的需求，但該技術仍在不斷發展，進一步提升其作為介入治療手段的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 內視鏡逆行性造影（ERCP）市場：依手術類型分類

  • 診斷
    • 造影
    • 造影
  • 治療
    • 括約肌切開術
    • 支架置入
    • 石材移除

第8章 內視鏡逆行性造影（ERCP）市場：依產品分類

  • 配件
  • 內視鏡系統
  • 影像系統
    • 光源
    • 影像處理設備

第9章 內視鏡逆行性造影（ERCP）市場：依應用領域分類

  • 膽道疾病
    • 膽結石
    • 洩漏
    • 收縮
  • 胰臟疾病
    • 胰臟炎
    • 瘤

第10章 內視鏡逆行性造影（ERCP）市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 內視鏡逆行性造影（ERCP）市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 內視鏡逆行性胰造影（ERCP）市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 內視鏡逆行性造影（ERCP）市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Ambu A/S
  • B. Braun Melsungen AG
  • Boston Scientific Corporation
  • Changzhou Health Microport Medical Device Co., Ltd.
  • CONMED Corporation
  • Cook Medical LLC
  • FUJIFILM Holdings Corporation
  • Hobbs Medical, Inc.
  • HOYA Corporation
  • Huger Medical Instrument Co., Ltd.
  • IntroMedic Co., Ltd.
  • Johnson & Johnson
  • KARL STORZ SE & Co. KG
  • Kimberly-Clark Corporation
  • Medi-Globe GmbH
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Olympus Corporation
  • Ottomed Healthcare Private Limited
  • Shaili Endoscopy Pvt. Ltd.
  • Shanghai AOHUA Photoelectricity Endoscope Co., Ltd.
  • SonoScape Medical Corp.
  • STERIS plc
  • Taewoong Medical Co., Ltd.
  • TeleMed Systems, Inc.
Product Code: MRR-5A2C6AA6657B

The Endoscopic Retrograde Cholangiopancreatography Market is projected to grow by USD 3.87 billion at a CAGR of 8.28% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.21 billion
Estimated Year [2026] USD 2.39 billion
Forecast Year [2032] USD 3.87 billion
CAGR (%) 8.28%

Endoscopic Retrograde Cholangiopancreatography Executive Summary

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a specialized, minimally invasive procedure used to diagnose and treat disorders of the biliary and pancreatic ductal systems, including choledocholithiasis, biliary strictures, pancreatic duct leaks, cholangitis, and malignant biliary obstruction. Combining endoscopy with fluoroscopic imaging, ERCP has evolved from a primarily diagnostic technique into a therapeutic cornerstone for gastroenterology, hepatobiliary care, and interventional endoscopy. Its clinical value is particularly significant in stone extraction, sphincterotomy, biliary stenting, tissue sampling, drainage, and management of post-surgical complications.

The ERCP landscape is shaped by rising clinical demand for minimally invasive treatment pathways, expanding availability of advanced endoscopic accessories, and growing emphasis on reducing procedure-related complications such as post-ERCP pancreatitis, bleeding, perforation, and infection. Current practice is increasingly guided by evidence-based patient selection, prophylactic pancreatic stenting in high-risk patients, rectal nonsteroidal anti-inflammatory drugs for pancreatitis prevention, radiation dose optimization, and improved cannulation techniques. In parallel, health systems are investing in multidisciplinary pancreaticobiliary programs, dedicated endoscopy suites, and structured training to improve procedural success and safety.

Search interest and clinical relevance are strongest around keywords such as therapeutic ERCP, biliary stents, pancreatic duct stents, sphincterotomes, cholangiography, endoscopic ultrasound-guided biliary drainage, cholangioscopy, and management of bile duct stones. These themes reflect a broader shift toward precision intervention, earlier disease management, and integration of ERCP with complementary modalities such as magnetic resonance cholangiopancreatography, endoscopic ultrasound, and cross-sectional imaging.

Transformative Shifts in the ERCP Landscape

The ERCP landscape is undergoing transformative change as the procedure becomes more therapeutic, technology-enabled, and safety-focused. Diagnostic ERCP has declined in many advanced care settings due to the wider use of noninvasive imaging, particularly magnetic resonance cholangiopancreatography and endoscopic ultrasound. As a result, ERCP is increasingly reserved for cases where direct intervention is expected, including bile duct stone removal, stent placement, decompression of obstructed ducts, and treatment of benign or malignant strictures.

Device innovation is reshaping procedural performance. Single-use duodenoscopes and disposable components are gaining attention because reusable duodenoscopes have been associated with infection transmission risks when reprocessing is inadequate or technically challenging. Improvements in duodenoscope design, elevator mechanisms, access catheters, guidewires, retrieval balloons, baskets, sphincterotomes, dilation balloons, plastic stents, and fully covered self-expandable metal stents are strengthening the therapeutic profile of ERCP. Meanwhile, cholangioscopy-assisted ERCP is improving visualization of intraductal pathology, targeted biopsies, difficult stone management, and evaluation of indeterminate strictures.

Clinical workflows are also shifting toward integrated pancreaticobiliary care. Many institutions now combine ERCP with endoscopic ultrasound, interventional radiology, surgical oncology, hepatology, and advanced imaging teams to determine the most appropriate treatment sequence. This is particularly important for malignant biliary obstruction, altered surgical anatomy, recurrent choledocholithiasis, and complex pancreatic duct disease. At the same time, payers and hospitals are emphasizing quality metrics, adverse event reporting, antibiotic stewardship, sedation safety, radiation exposure management, and documented indications to ensure that ERCP is used when its therapeutic benefit outweighs procedural risk.

Cumulative Impact of Artificial Intelligence on ERCP

Artificial intelligence is beginning to influence the ERCP ecosystem through image interpretation, workflow optimization, clinical decision support, training, and quality improvement. While AI is more mature in luminal endoscopy applications such as computer-aided lesion detection, its relevance to ERCP is growing as high-quality procedural videos, fluoroscopic images, electronic health records, and endoscopy reporting systems become more structured and analyzable.

AI-enabled tools can support pre-procedure risk stratification by integrating patient factors associated with post-ERCP pancreatitis, difficult cannulation, bleeding risk, infection risk, and need for alternative drainage. Intra-procedural applications may include recognition of cannulation attempts, papillary orientation, fluoroscopic anatomy, stone burden, stricture characteristics, and stent positioning. In training environments, AI-assisted video review can help identify technique patterns linked to successful cannulation, reduced pancreatic duct trauma, shorter fluoroscopy time, and lower adverse event rates.

The cumulative impact of AI will depend on validated datasets, transparent algorithms, clinician oversight, cybersecurity safeguards, and regulatory alignment for software used in procedural decision-making. Near-term value is expected from documentation automation, procedure coding support, quality benchmarking, and complication prediction models. Over time, AI may help standardize ERCP quality across high-volume referral centers and emerging advanced endoscopy programs by improving case selection, reducing variability, and supporting evidence-based procedural planning without replacing expert clinical judgment.

Key Regional Insights for ERCP Adoption

In Asia-Pacific, ERCP utilization is supported by rising access to advanced endoscopy services, a large patient base with gallstone disease and hepatobiliary disorders, expanding tertiary care networks, and growing adoption of endoscopic ultrasound and cholangioscopy in major urban hospitals. Countries with mature healthcare infrastructure are emphasizing high-volume endoscopy centers, infection-control protocols, advanced fluoroscopy access, and therapeutic endoscopy training, while emerging systems are prioritizing capacity building, specialist availability, and reliable access to essential ERCP accessories.

North America demonstrates strong integration of ERCP into multidisciplinary care for biliary obstruction, pancreaticobiliary malignancy, choledocholithiasis, and post-transplant or post-surgical biliary complications. The region places significant emphasis on procedure appropriateness, quality reporting, adverse event mitigation, duodenoscope reprocessing standards, and adoption of single-use technologies where infection prevention and operational efficiency justify use. Training pathways, credentialing standards, and evidence-based prophylaxis for post-ERCP pancreatitis are central to maintaining ERCP safety.

Latin America is advancing ERCP access through public and private hospital investments, regional referral pathways, and growing demand for minimally invasive management of bile duct stones, pancreatitis-related ductal disease, and obstructive jaundice. Variation in access between metropolitan and rural areas remains a major determinant of procedural availability, making workforce development, equipment distribution, maintenance capacity, and affordability of consumables key strategic priorities.

Europe has a well-established ERCP practice environment supported by clinical guidelines, quality indicators, structured endoscopy training, and strong emphasis on infection prevention and device surveillance. The region continues to adopt evidence-based approaches for preventing post-ERCP pancreatitis, optimizing biliary stenting decisions, and selecting patients for ERCP after noninvasive imaging confirmation. Cross-border consistency is strengthened by guideline-driven care, although reimbursement, procurement, and service configuration models differ by country.

The Middle East is expanding advanced endoscopy capabilities through investment in tertiary hospitals, medical tourism hubs, and specialized gastroenterology programs. ERCP demand is linked to gallstone disease, biliary strictures, pancreatic disease, and oncologic care pathways. In higher-income health systems, adoption of modern fluoroscopy systems, disposable accessories, and advanced therapeutic endoscopy is progressing rapidly, while broader regional access remains influenced by workforce depth, referral infrastructure, and concentration of specialized services.

Africa presents a more uneven ERCP landscape, with services concentrated in major urban and academic centers. The region faces constraints related to specialist training, equipment availability, maintenance capacity, fluoroscopy access, and affordability of accessories. However, the clinical need for therapeutic biliary drainage, stone extraction, and management of obstructive jaundice is substantial. Partnerships focused on training, sustainable procurement, biomedical engineering support, and regional centers of excellence are critical to improving safe ERCP access.

Key Group Insights Across Healthcare and Economic Blocs

Within ASEAN, ERCP growth is shaped by expanding tertiary care infrastructure, rising diagnosis of gastrointestinal and hepatobiliary disease, and increasing investment in advanced endoscopy units across urban centers. The region's diversity creates different adoption speeds, with more developed health systems emphasizing complex therapeutic ERCP and emerging markets prioritizing broader access to trained endoscopists, fluoroscopy support, reprocessing capacity, and essential accessories.

The GCC is characterized by strong healthcare infrastructure investment, rapid adoption of advanced endoscopic technologies, and growing demand for specialized pancreaticobiliary services. ERCP is integrated into tertiary hospitals, private specialty centers, and medical tourism-oriented care models, with quality, patient safety, infection prevention, and procedural efficiency positioned as procurement and operational priorities.

The European Union benefits from harmonized clinical guidance, regulatory scrutiny of medical devices, structured quality initiatives, and widespread availability of noninvasive imaging that supports appropriate ERCP use. EU healthcare systems increasingly focus on reducing unnecessary diagnostic ERCP, improving documentation, preventing post-procedure pancreatitis, ensuring safe reprocessing, and evaluating controlled use of single-use components in high-risk settings.

BRICS countries represent a heterogeneous but influential ERCP environment, combining large patient populations, expanding hospital networks, and varying levels of advanced endoscopy maturity. China and India are scaling access through major hospital systems and specialist training, Brazil and South Africa serve as regional referral anchors in many settings, and Russia maintains established gastroenterology services with regional differences in technology penetration, workforce density, and advanced accessory availability.

The G7 countries demonstrate mature ERCP utilization, strong advanced endoscopy training frameworks, high adoption of guideline-based care, and extensive integration of ERCP with endoscopic ultrasound, oncology, hepatology, and surgery. These countries are often early evaluators of infection-control innovations, AI-enabled documentation, quality analytics, adverse event prevention protocols, and advanced biliary and pancreatic stenting strategies.

NATO countries, considered through a healthcare-readiness lens rather than a commercial bloc, include many systems with developed hospital infrastructure and established emergency care pathways for acute cholangitis, gallstone pancreatitis, and obstructive jaundice. ERCP capability in these countries is closely tied to tertiary referral networks, emergency endoscopy availability, standardized infection prevention practices, and continuity of supply for critical endoscopic accessories.

Key Country Insights in Endoscopic Retrograde Cholangiopancreatography

The United States has a highly developed ERCP ecosystem supported by advanced endoscopy fellowship training, robust hospital-based pancreaticobiliary programs, and strong attention to duodenoscope safety, post-ERCP pancreatitis prevention, and procedure quality indicators. Canada similarly emphasizes evidence-based use, centralized advanced endoscopy expertise, and equitable access challenges across geographically dispersed populations. Mexico is strengthening ERCP availability through urban specialty centers and private-sector investment, while public-sector access, reimbursement variability, and trained workforce distribution continue to shape procedural reach.

Brazil is a major Latin American center for therapeutic endoscopy, with ERCP services concentrated in larger hospitals and referral institutions that manage bile duct stones, obstructive jaundice, and pancreaticobiliary malignancies. In Europe, the United Kingdom, Germany, France, Italy, and Spain maintain established ERCP programs supported by guideline-based patient selection, multidisciplinary cancer pathways, and quality assurance systems. Germany and France have extensive specialist infrastructure, the United Kingdom emphasizes national-level clinical governance and referral pathways, while Italy and Spain show strong use of ERCP in hepatobiliary and surgical complication management. Russia has established ERCP practice in major cities and academic centers, though regional access, equipment renewal, and technology availability vary.

China is rapidly expanding advanced endoscopy capacity through large tertiary hospitals, training programs, and adoption of therapeutic ERCP for biliary and pancreatic diseases. India has increasing demand due to a large gastrointestinal disease burden and expanding private and academic hospital networks, with access remaining strongest in metropolitan centers and high-volume referral hospitals. Japan is a global leader in endoscopic technique refinement, pancreaticobiliary imaging, cholangioscopy, and complex therapeutic ERCP, supported by high procedural expertise and strong clinical research culture. Australia offers advanced ERCP services through tertiary and regional referral networks, with emphasis on safety, credentialing, and access across dispersed geography. South Korea demonstrates sophisticated adoption of ERCP, endoscopic ultrasound integration, and advanced biliary interventions through highly specialized centers and strong procedural training standards.

Actionable Recommendations for ERCP Industry Leaders

Industry leaders should prioritize technologies and services that improve ERCP safety, therapeutic precision, and workflow reliability. Device developers can focus on accessories that reduce cannulation trauma, improve stone extraction, enhance stent deployment accuracy, and support complex anatomy. Greater attention to single-use or easier-to-reprocess components can address persistent infection-control concerns associated with duodenoscope design and cleaning complexity.

Healthcare providers should strengthen ERCP governance by implementing indication-based scheduling, standardized consent, prophylaxis for post-ERCP pancreatitis, radiation safety protocols, adverse event tracking, antibiotic stewardship, and competency-based credentialing. Hospitals can improve outcomes by concentrating complex ERCP cases in high-expertise centers while maintaining emergency access for acute cholangitis and urgent biliary decompression.

Training organizations should expand simulation-based learning, video-based performance review, and structured mentorship for cannulation, sphincterotomy, stenting, cholangioscopy, and rescue techniques. Digital infrastructure investments should prioritize interoperable endoscopy reporting, AI-ready procedural data, automated quality dashboards, and secure image archives. Procurement teams should evaluate devices not only on acquisition cost but also on clinical performance, reprocessing burden, infection risk, durability, staff training requirements, and compatibility with existing imaging platforms.

Research Methodology for ERCP Insights

This executive summary is developed through a structured secondary research approach focused on clinically validated and industry-relevant information. The methodology incorporates peer-reviewed gastroenterology literature, international clinical practice guidelines, regulatory safety communications, public health agency materials, hospital quality frameworks, and documented standards for endoscope reprocessing, procedural safety, and adverse event prevention.

The analysis prioritizes verified evidence on ERCP indications, therapeutic applications, procedural risks, device evolution, infection-control practices, training requirements, and regional healthcare infrastructure. Sources are assessed for credibility, recency, methodological quality, and relevance to endoscopic retrograde cholangiopancreatography. Insights are synthesized qualitatively to identify technology trends, adoption drivers, clinical workflow changes, and regional access dynamics.

The research approach deliberately excludes market sizing, revenue estimation, market share calculation, and forecasting. Instead, it emphasizes evidence-backed interpretation of clinical practice patterns, regulatory considerations, healthcare delivery realities, and innovation pathways. Geographic and group-level insights are developed by comparing healthcare infrastructure maturity, specialist availability, clinical guideline adoption, reimbursement context, infection-control capability, and access to advanced endoscopy resources.

Conclusion: ERCP as a Precision Therapeutic Platform

Endoscopic Retrograde Cholangiopancreatography remains a critical therapeutic procedure for pancreaticobiliary disease, particularly when patients require bile duct stone extraction, biliary drainage, stent placement, sphincterotomy, tissue acquisition, or treatment of complex strictures. Its role continues to evolve as noninvasive diagnostic imaging reduces the need for purely diagnostic ERCP and reinforces the procedure's value as an interventional platform.

The next phase of ERCP advancement will be defined by safer device design, stronger infection-control strategies, broader access to advanced endoscopy training, integration with endoscopic ultrasound and cholangioscopy, and careful use of artificial intelligence for risk stratification, quality monitoring, documentation, and procedural support. Regional and country-level differences in infrastructure, workforce, and reimbursement will continue to influence access, but the clinical direction is consistent: ERCP is becoming more selective, more therapeutic, more data-driven, and more accountable to quality outcomes.

For healthcare leaders, device innovators, and advanced endoscopy programs, the strategic imperative is to align technology adoption with patient safety, procedural effectiveness, and sustainable care delivery. Organizations that invest in training, evidence-based protocols, interoperable data systems, infection prevention, and complication reduction will be best positioned to meet the growing clinical need for high-quality pancreaticobiliary intervention.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endoscopic Retrograde Cholangiopancreatography Market, by Procedure Type

  • 7.1. Introduction
  • 7.2. Diagnostic
    • 7.2.1. Cholangiography
    • 7.2.2. Pancreatography
  • 7.3. Therapeutic
    • 7.3.1. Sphincterotomy
    • 7.3.2. Stent Placement
    • 7.3.3. Stone Extraction

8. Endoscopic Retrograde Cholangiopancreatography Market, by Product

  • 8.1. Introduction
  • 8.2. Accessories
  • 8.3. Endoscope Systems
  • 8.4. Imaging Systems
    • 8.4.1. Light Sources
    • 8.4.2. Video Processors

9. Endoscopic Retrograde Cholangiopancreatography Market, by Application

  • 9.1. Introduction
  • 9.2. Biliary System Disorders
    • 9.2.1. Gallstones
    • 9.2.2. Leaks
    • 9.2.3. Strictures
  • 9.3. Pancreatic System Disorders
    • 9.3.1. Pancreatitis
    • 9.3.2. Tumors

10. Endoscopic Retrograde Cholangiopancreatography Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Endoscopic Retrograde Cholangiopancreatography Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Endoscopic Retrograde Cholangiopancreatography Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Endoscopic Retrograde Cholangiopancreatography Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. FPNV Positioning Matrix, 2025
  • 14.3. Market Concentration Analysis, 2025
    • 14.3.1. Concentration Ratio (CR)
    • 14.3.2. Herfindahl Hirschman Index (HHI)
  • 14.4. Recent Developments & Impact Analysis, 2025
  • 14.5. Product Portfolio Analysis, 2025
  • 14.6. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Ambu A/S
  • 15.2. B. Braun Melsungen AG
  • 15.3. Boston Scientific Corporation
  • 15.4. Changzhou Health Microport Medical Device Co., Ltd.
  • 15.5. CONMED Corporation
  • 15.6. Cook Medical LLC
  • 15.7. FUJIFILM Holdings Corporation
  • 15.8. Hobbs Medical, Inc.
  • 15.9. HOYA Corporation
  • 15.10. Huger Medical Instrument Co., Ltd.
  • 15.11. IntroMedic Co., Ltd.
  • 15.12. Johnson & Johnson
  • 15.13. KARL STORZ SE & Co. KG
  • 15.14. Kimberly-Clark Corporation
  • 15.15. Medi-Globe GmbH
  • 15.16. Medtronic plc
  • 15.17. Merit Medical Systems, Inc.
  • 15.18. Olympus Corporation
  • 15.19. Ottomed Healthcare Private Limited
  • 15.20. Shaili Endoscopy Pvt. Ltd.
  • 15.21. Shanghai AOHUA Photoelectricity Endoscope Co., Ltd.
  • 15.22. SonoScape Medical Corp.
  • 15.23. STERIS plc
  • 15.24. Taewoong Medical Co., Ltd.
  • 15.25. TeleMed Systems, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 21. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOLANGIOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHOLANGIOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOLANGIOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THERAPEUTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THERAPEUTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THERAPEUTIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SPHINCTEROTOMY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SPHINCTEROTOMY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SPHINCTEROTOMY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STENT PLACEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL STENT PLACEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL STENT PLACEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL STONE EXTRACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL STONE EXTRACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL STONE EXTRACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACCESSORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACCESSORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACCESSORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENDOSCOPE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ENDOSCOPE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ENDOSCOPE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMAGING SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIGHT SOURCES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIGHT SOURCES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIGHT SOURCES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL VIDEO PROCESSORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL VIDEO PROCESSORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL VIDEO PROCESSORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BILIARY SYSTEM DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BILIARY SYSTEM DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BILIARY SYSTEM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GALLSTONES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GALLSTONES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GALLSTONES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LEAKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LEAKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LEAKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STRICTURES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL STRICTURES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL STRICTURES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PANCREATIC SYSTEM DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PANCREATIC SYSTEM DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PANCREATIC SYSTEM DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PANCREATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PANCREATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PANCREATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TUMORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUMORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUMORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 148. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 184. G7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 189. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 190. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 191. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 193. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 225. MEXICO ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 234. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 235. BRAZIL ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED KINGDOM ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 262. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 263. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 270. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 271. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 272. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 274. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 275. RUSSIA ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 279. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 280. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 281. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PANCREATIC SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 289. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 290. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 291. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY IMAGING SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 292. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 293. SPAIN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SIZE, BY BILIARY SYSTEM DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 294. SPAIN ENDOSCOPIC RETROGRADE